Decitabine (a related DNMT inhibitor) stimulated the cytotoxic and infiltration responses of CD8+ T cells, which combined with anti-CTLA-4 antibody exhibited synergistic anti-tumor effects and extended survival in a syngeneic murine ovarian cancer model [142]. This evidence concerns the gene CD8A and neoplasm.